PMC:7299399 / 8456-8900 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T45","span":{"begin":97,"end":113},"obj":"Disease"},{"id":"T46","span":{"begin":170,"end":178},"obj":"Disease"}],"attributes":[{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).\nIn the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.32−34 I"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T82","span":{"begin":48,"end":51},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T83","span":{"begin":237,"end":240},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T84","span":{"begin":379,"end":380},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T85","span":{"begin":405,"end":412},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T86","span":{"begin":440,"end":442},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"}],"text":" resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).\nIn the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.32−34 I"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T37","span":{"begin":160,"end":165},"obj":"Chemical"},{"id":"T38","span":{"begin":288,"end":297},"obj":"Chemical"}],"attributes":[{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":" resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).\nIn the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.32−34 I"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T18","span":{"begin":97,"end":113},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":" resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).\nIn the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.32−34 I"}

{"project":"LitCovid-sentences","denotations":[{"id":"T41","span":{"begin":115,"end":210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).\nIn the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.32−34 I"}

{"project":"LitCovid-PubTator","denotations":[{"id":"166","span":{"begin":170,"end":180},"obj":"Species"},{"id":"167","span":{"begin":97,"end":113},"obj":"Disease"}],"attributes":[{"id":"A166","pred":"tao:has_database_id","subj":"166","obj":"Tax:2697049"},{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).\nIn the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.32−34 I"}

{"project":"2_test","denotations":[{"id":"32519842-32194980-158464","span":{"begin":203,"end":205},"obj":"32194980"},{"id":"32519842-27575283-158465","span":{"begin":437,"end":439},"obj":"27575283"},{"id":"32519842-26551316-158466","span":{"begin":440,"end":442},"obj":"26551316"}],"text":" resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).\nIn the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.32−34 I"}